Sichuan Huiyu Pharmaceuticals Co. Ltd. and Sichuan Huiyu Seacross Pharma Technology Ltd. have jointly described new phosphatidylinositol 3-kinase (PI3K) and/or GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer and autoimmune diseases.
Immuther Pharmtech (Shanghai) Co. Ltd. has patented lysophosphatidic acid LPA5 receptor (GPR92) antagonists reported to be useful for the treatment of neuropathic pain, cancer, neurological disorders, atherosclerosis, inflammatory and autoimmune diseases, fibrosis and obesity, among others.
Deep Genomics Inc. has introduced its artificial intelligence (AI) foundation model for RNA, BigRNA, which enables discovery of disease mechanisms and candidate therapeutics.
Twist Bioscience Corp. and Imidomics Inc. have established a multi-program collaboration whereby Twist will utilize its antigen development capabilities and Library of Libraries to conduct antibody discovery activities against targets identified by Imidomics.
Kriya Therapeutics Inc. has entered into an exclusive license, collaboration and supply agreement with Everads Therapy Ltd. to advance Kriya’s portfolio of gene therapies for retinal diseases using Everads’ suprachoroidal delivery device.
Researchers from the University of Minnesota and collaborators have synthesized and evaluated a novel series of antiproliferative benzofuran derivatives that led to the identification of [I] as the most potent candidate.
Pathios Therapeutics Ltd. has been awarded a £567,000 (~US$727,000) grant from the U.K. Government’s innovation agency, Innovate UK, that will enable the company to expand its development of novel small-molecule GPR65 inhibitors into the area of malignant brain tumors.
Researchers from Birla Institute of Technology & Science, Pilani and Jadavpur University have reported novel HDAC3 inhibitors as potential candidates for the treatment of breast cancer. Synthesis and optimization of a series of pyrazino-hydrazide-based HDAC3 inhibitors led to the characterization of compound [I] as the lead candidate with potent HDAC3 inhibitory activity (IC50=14 nM) and at least 121-fold selectivity.
Among all human papillomavirus (HPV) types described so far, the two most abundant – HPV16 and HPV18 – are responsible for 71% of all cervical cancers. The vaccines currently used are effective in preventing viral infection, but have no effect on already infected or maligned cells.
RSS
